Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

484 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R, Lodise TP, Naas T, Niki Y, Paterson DL, Portsmouth S, Torre-Cisneros J, Toyoizumi K, Wunderink RG, Nagata TD. Bassetti M, et al. Among authors: niki y. Lancet Infect Dis. 2021 Feb;21(2):226-240. doi: 10.1016/S1473-3099(20)30796-9. Epub 2020 Oct 12. Lancet Infect Dis. 2021. PMID: 33058795 Clinical Trial.
All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies.
Lodise TP, Bassetti M, Ferrer R, Naas T, Niki Y, Paterson DL, Zeitlinger M, Echols R. Lodise TP, et al. Among authors: niki y. Expert Rev Anti Infect Ther. 2022 May;20(5):707-719. doi: 10.1080/14787210.2022.2020099. Epub 2022 Jan 12. Expert Rev Anti Infect Ther. 2022. PMID: 34937518 Review.
[In-vitro susceptibilites to levofloxacin and various antibacterial agents of 18,639 clinical isolates obtained from 77 centers in 2004].
Yamaguchi K, Ohno A, Ishii Y, Tateda K, Iwata M, Kanda M, Tsujio Y, Kimoto H, Kaimori M, Nakamura T, Kawamura C, Nishimura M, Akizawa K, Katayama Y, Matsuda K, Hayashi T, Yasujima M, Kasai T, Kimura M, Tominaga M, Miki M, Nakanowatari S, Nakagawa T, Kaku M, Kanemitsu K, Kunishima H, Toyoshima S, Sakurai M, Shiotani J, Sugita A, Ito T, Okada J, Suwabe A, Yamahata K, Yoneyama A, Kumasaka K, Yamane N, Koike K, Ieiri T, Kominami H, Yamada T, Oguri T, Itoh K, Watanabe K, Kobayashi Y, Ohtake T, Uchida T, Totsuka K, Murakami M, Yomoda S, Takahashi A, Okamoto H, Inuzuka K, Yamazaki K, Gonda H, Yamashita T, Yamaguchi I, Okada M, Ikari H, Kurosawa N, Fujimoto Y, Ishigo S, Asano Y, Mikio M, Kano I, Nagano E, Kageyama F, Shaku E, Kanno H, Aihara M, Gemma H, Uemura K, Miyajima E, Maesaki S, Hashikita G, Horii T, Sumitomo M, Yoshimura H, Hiraoka M, Wada H, Yuzuki Y, Ikeda N, Baba H, Soma M, Yamamoto T, Ichiyama S, Kinosita S, Kawano S, Fujita S, Kageoka T, Hongo T, Okabe H, Tatewaki K, Moro K, Oka M, Niki Y, Yoshida H, Yamashita M, Kusano N, Mihara E, Nose M, Fushiwaki T, Kuwabara M, Fujiue Y, Shimuzu A, Takubo T, Kusakabe T, Hinoda Y, Tanaka N, Takahashi H, Heijyou H, Okazaki T, Asai K,… See abstract for full author list ➔ Yamaguchi K, et al. Among authors: niki y. Jpn J Antibiot. 2006 Dec;59(6):428-51. Jpn J Antibiot. 2006. PMID: 17334061 Japanese.
Evaluation of clinical dosage of gatifloxacin for respiratory tract infections in elderly patients based on pharmacokinetics/pharmacodynamics (PK/PD).
Niki Y, Yoshida K, Miyashita N, Oka M, Hara H, Kishimoto M, Okimoto N, Kawanishi M, Uno M, Kamao T, Yoneyama H, Nakamura J, Kimura M, Watanabe M, Tanimukai T, Moriya O, Matsushima T. Niki Y, et al. J Infect Chemother. 2008 Aug;14(4):296-304. doi: 10.1007/s10156-008-0625-0. Epub 2008 Aug 17. J Infect Chemother. 2008. PMID: 18709533 Clinical Trial.
484 results